Hem/Onc Board Review

742 posts

Hem/Onc Board Review

@Hemoncq

Hematology/oncology board review style questions. By @ahmadalhader and @DrM_AbuZaid

Indianapolis, IN Katılım Ekim 2020

490 Takip Edilen1.8K Takipçiler

Hem/Onc Board Review retweetledi

Omar Abu Ghanimeh@omarabughanimeh·1 Haz

Proud to be an investigator in the head and neck cohort of SGN35-033. Our data was discussed today at @ASCO, showing promising clinical efficacy of BV + Pembro in treatment -naive patients with metastatic HNSCC and CPS ≥1. meetings.asco.org/abstracts-pres… @NebraskaMed @UNMCHemeOnc

English

969

Hem/Onc Board Review retweetledi

Indiana University Hematology/Oncology Fellowship@IUHemOnc·31 May

Congrats to chief fellow @Noah_Onc for their @ConquerCancerFd Young Investigator Award investigating novel prostate cancer therapeutics and our brilliant faculty member @drshieldsmd Career Development Award in lung cancer. #ASCO2025 is off to a great start! @IUCancerCenter

Indiana University Hematology/Oncology Fellowship tweet media

English

4.5K

Hem/Onc Board Review retweetledi

TwoOncDocs@TwoOncDocs·30 May

Thank you all who joined Clinicals to Exams & guest appearance w/ baby Cary A few high-yield mnemonics: 🌟 ribociclib - “ribs” close to ❤️- Qtc; abemaciclib - “abs” - diarrhea 🌟 tumor marker half-life: Hcg -3 letters, 1-3d; AFP -alpha - 5 letters 5-7d Ready for #ASCO25 day 1!

English

Hem/Onc Board Review retweetledi

TwoOncDocs@TwoOncDocs·1 Eki

This week’s episode we discussed our favorite heme/onc board review resources - books, Qbanks, podcasts ect 📕 🖥️ 🎙️ podcasts.apple.com/us/podcast/two…

English

3.7K

Hem/Onc Board Review@Hemoncq·19 Eyl

@DrChoueiri @myESMO @OncoAlert @TheLancet @Uromigos @brian_rini @montypal @AlbigesL @motzermd Some wishful thinking. But do you think the type of progression on IO matters? Primary resistance vs secondary resistance? Slow progression with no new sites vs more rapid progression with new sites of disease? Mets location: lung vs other immunoresistant sites like liver?

English

Toni Choueiri, MD@DrChoueiri·16 Eyl

The results for the poll for PD1/L1 rechallenge is out: Despite 2 negative phase 3 trials with Atezo and Nivo, 22% believe we should repeat a study with pembrolizumab @myESMO @OncoAlert @TheLancet @Uromigos @brian_rini @montypal @AlbigesL @motzermd

English

4.9K

Hem/Onc Board Review@Hemoncq·15 Eyl

@brian_rini But low blow to mention reimbursement rates for IO here It is ineffective but most of the use is due to wishful thinking and wanting to help rather than financial and malicious

English

Brian Rini, MD@brian_rini·14 Eyl

Exactly. The responsibility falls to providers to give patients therapy with maximal benefit/risk. If no benefit, then it’s all risk. The persistence of this practice in the face of negative data is the desperation to help patients, but in fact results in more harm.

Dena Battle@RCCadvocate

Does TiVo/nivo close the door on IO post IO? Why was the door ever open? Where is the data supporting continuing IO after failure? For desperate #kidneycancer patients, more always feels better. And far too many oncologists are happy to oblige given the high reimbursement rates for these infusions. Hopefully this trial + CONTACT3 will stem the tide of needless toxicity. Practice changing? Yes. But should it be? No. #ESMO2024

English

6.4K

Hem/Onc Board Review retweetledi

Indiana University Hematology/Oncology Fellowship@IUHemOnc·2 Ağu

Our fellow @AhmedBilalKhal2 recently attended the ASCR/ASCO Methods in Clinical Cancer Research Workshop to continue developing a clinical trial with our excellent GU faculty. Way to go!

Ahmed Bilal Khalid@AhmedBilalKhal2

Thankful to my mentors @JenniferKingMD and @nabiladra and to @AACR and @ASCO for this wonderful opportunity to attend the AACR/ASCO Methods in Clinical Cancer Research Workshop and learn clinical trial and protocol design. @IUHemOnc @IUCancerCenter

English

1.2K

Hem/Onc Board Review retweetledi

Indiana University Hematology/Oncology Fellowship@IUHemOnc·2 Ağu

Our fellow @Noah_Onc attended the AACR Molecular Biology in Clinical Oncology workshop, focused on molecular biology, translational cancer research, career development, and grant writing for the aspiring physician-scientist. Congrats! @IUCancerCenter

English

958

Hem/Onc Board Review@Hemoncq·31 Tem

Great opportunity. One of 6 combined programs in the country! Facilitated by @ASCO

Indiana University Hematology/Oncology Fellowship@IUHemOnc

We are still accepting applications for our combined Hem/Onc & Palliative/Hospice medicine fellowship. It is a 3 year program eligible for the Hematology, Medical Oncology and Palliative Care boards. @ASCO @IUHPMFellows society.asco.org/meetings-educa…

English

503

Hem/Onc Board Review@Hemoncq·20 Tem

Definitely! For the boards, you don’t necessarily need to know the studies or the actual evidence (for the most part). You need to know first line, second line tx, etc

Jennifer A. Marks, MD@jennifermarksmd

To my friends studying for boards, I highly recommend downloading the @ASCO #guidelines app. @ASCOTECAG Also -here are some excellent #Ovariancancer algorithms. @ABIMcert #gynsm #MedTwitter #OncTwitter link.springer.com/article/10.100…

English

1.3K

Hem/Onc Board Review retweetledi

TwoOncDocs@TwoOncDocs·6 May

We are back this week with @tompowles1 & @brian_rini diving into metastatic RCC! We discuss risk stratification, their differing opinions around cytoreductive nephrectomy, 1L tx & sequencing, pearls regarding sarcomatoid, non-clear-cell RCC & tips for trainees @Uromigos

English

2.6K

Hem/Onc Board Review@Hemoncq·9 Oca

@EladSharonMD @thenasheffect @ADesaiMD @MyriamChalabi @DrJNaidoo @drbrucejohnson @gulleyj1 @SashaGusevPosts @VivekSubbiah @tmprowell @jitcancer @eaonc I’ll double down and ask about melanoma. Present in < 1% as well If I get an MSI-hi melanoma, would it tempt me to give single agent anti-PD1? Risk for undertreating? Agree with the sentiment of checking MSI on all solid tumors, especially when ICIs aren’t part of 1st line tx

English

Elad Sharon@EladSharonMD·9 Oca

@thenasheffect @ADesaiMD @MyriamChalabi @DrJNaidoo @drbrucejohnson @gulleyj1 @SashaGusevPosts @VivekSubbiah @tmprowell @jitcancer One issue is the potential for backing off of therapy… in other words, would you need chemo in a patient with MSI-high lung cancer? Might be worth seeing subsets (even if small) on a trial like @eaonc EA5163: clinicaltrials.gov/study/NCT03793…

English

Elad Sharon@EladSharonMD·9 Oca

Now let’s have every single solid tumor patient get tested for MSI-high status… @thenasheffect @MyriamChalabi @DrJNaidoo @drbrucejohnson @gulleyj1 @SashaGusevPosts @VivekSubbiah @tmprowell @jitcancer

𝙅𝙚𝙨𝙪𝙨 𝘼𝙣𝙖𝙢𝙥𝙖 𝙈.𝘿, 𝙈.𝙎🧬🔬@jesusanampa

Updated @ASCO guidelines for Germline Testing in Patients With Breast Cancer. BRCA1/2 testing offered to all newly diagnosed ≤65 yrs and select patients >65 years based on personal history, family history, ancestry, or eligibility for PARPi #BCSM ascopubs.org/doi/full/10.12…

English

7.2K

Hem/Onc Board Review@Hemoncq·6 Oca

@pashtoonkasi @fernandbteich @agrothey @HKennecke @FightCRC @CCAlliance @marklewismd @ShaalanBeg @cancerassassin1 @DocDustyD @mtmdphd @PresOnc_Connect @NTRKers @OncLive @VivekSubbiah Pashtoon, what do you do with MSI-H, braf-V600 post progression on Pembro? I generally give Ipi/Nivo a try for 3 months. Then BEACON. Then chemo + Bev Does it make a difference if primary or secondary resistance to Pembro?

English

116

Pashtoon Kasi MD, MS@pashtoonkasi·6 Oca

@fernandbteich @agrothey @HKennecke @FightCRC @CCAlliance @marklewismd @ShaalanBeg @cancerassassin1 @DocDustyD @mtmdphd @PresOnc_Connect @NTRKers @OncLive Overall, it’s a good problem to have 2 strong drivers. Fusions tend to be seen higher in the MSI-High subset of colorectal cancers. Immunotherapy would still be the 1st choice till we get more data. And💊for the fusion if no response. @VivekSubbiah any experience with RET & MSI?

Queens, NY 🇺🇸 English

257

Axel Grothey@agrothey·28 Tem

Patient with mCRC, MSI-H, BRAF V600E mutated. First line pembro, now PD. What is your preferred second-line therapy?

English

Hem/Onc Board Review retweetledi

Indiana University Hematology/Oncology Fellowship@IUHemOnc·30 Kas

We are very excited to welcome our new class of fellows matched @IUHemOnc Congratulations! We are THRILLED to have you join us and looking forward to welcoming all of you! @IUCancerCenter

English

7.2K

Hem/Onc Board Review@Hemoncq·5 Haz

@JackWestMD @SuyogCancer @PatelOncology @FordePatrick @StephenVLiu @BijoyTelivala @CathyEngMD @Tony_Calles @ASCO @OncoAlert 💯

QME

148

H. Jack West, MD, FASCO@JackWestMD·5 Haz

@SuyogCancer @PatelOncology @FordePatrick @StephenVLiu @BijoyTelivala @CathyEngMD @Tony_Calles @ASCO @OncoAlert IMO, flaws are regrettable, & I don't like to feel manipulated by suboptimal execution that invariably helps sponsor company, but OS curves are impressive. We're never going to get trial that overcomes these probs. Adjuv osi is SOC based on major DFS diff, & OS further supports.

English

389

Dr Amol Akhade@SuyogCancer·4 Haz

So ADAURA is 100 % Osi for 3 years vs 23 % OSi Is this what we wanted ? Is this fair ? #ASCO23 @JackWestMD @PatelOncology @FordePatrick @StephenVLiu @BijoyTelivala @CathyEngMD @Tony_Calles @ASCO @OncoAlert

English

27.3K

Hem/Onc Board Review@Hemoncq·5 Haz

@SuyogCancer @PatelOncology @JackWestMD @FordePatrick @StephenVLiu @BijoyTelivala @CathyEngMD @Tony_Calles @ASCO @OncoAlert Who is coming up with this misleading 23% A good 30% or so never progressed and didn’t need to be on Osi

English

102

Dr Amol Akhade@SuyogCancer·4 Haz

@PatelOncology @JackWestMD @FordePatrick @StephenVLiu @BijoyTelivala @CathyEngMD @Tony_Calles @ASCO @OncoAlert Will the OS difference be the same if control arm has more acess Than 23 % ? Probably NO .

English

943

Hem/Onc Board Review retweetledi

Ziad Bakouny, MD, MSc@ZiadBakouny·4 Haz

Now @DrRoyHerbstYale with the third presentation of the plenary session with the #ADAURA study. Now with an overall survival benefit with osimertinib in patients with EGFR+ NSCLC. @ASCO #ASCO23 @YaleCancer @YaleMed @IMG_Oncologists @OncoAlert @HemOncToday @HemOncFellows @Hemoncq

English

6.7K

Hem/Onc Board Review@Hemoncq·4 Haz

@ZiadBakouny @MSK_DeptOfMed @ASCO @MSKCancerCenter @OncoAlert @HemOncToday @HemOncFellows @DrChoueiri @eddy_saad @Chrislabaki1 @ReneeSaliby @TarekHaykal1 @NazliDizman @KarlSemaan @neerajaiims Looking forward to the discussion Radiation free PROSPECT regimen vs the newer total neoadjuvant regimens with short course radiation

English

246

Hem/Onc Board Review retweetledi

Ziad Bakouny, MD, MSc@ZiadBakouny·4 Haz

My future boss @MSK_DeptOfMed, Dr. Deborah Schrag, now taking the stage to present the results of the PROSPECT trial evaluating chemoradiation vs FOLFOX for locally advanced rectal cancer. @ASCO #ASCO23 @MSKCancerCenter @OncoAlert @HemOncToday @HemOncFellows @Hemoncq

English

16.1K

Hem/Onc Board Review retweetledi

Eric K. Singhi, MD@lungoncdoc·24 Nis

☣️ Rare but life-threatening irAEs can have a lasting impact on our patients. #OncTwitter, how do you strike a balance between effectively obtaining IO consent & communicating potential serious irAEs to patients without undue distress? @JackWestMD @DrJNaidoo @jillfeldman4

English

28.7K

Keşfet

@ASCO @NebraskaMed @UNMCHemeOnc @Noah_Onc @ConquerCancerFd @drshieldsmd @IUCancerCenter @DrChoueiri